Response to a recently published systematic review on intranasal esketamine for major depressive disorder.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of affective disorders"
DOI: 10.1016/j.jad.2020.04.026
Abstract: A recently published meta-analysis on the use of intranasal esketamine for the treatment of major depressive disorder included a mistake in the data analysis. This letter explains the error and offers an alternative analysis. Fortunately… read more here.
Keywords: depressive disorder; intranasal esketamine; recently published; major depressive ... See more keywords
The acute antisuicidal effects of single-dose intravenous ketamine and intranasal esketamine in individuals with major depression and bipolar disorders: A systematic review and meta-analysis.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of psychiatric research"
DOI: 10.1016/j.jpsychires.2020.12.038
Abstract: The efficacy of ketamine in reducing suicidal ideation (SI) has been previously reported. We aimed to evaluate acute anti-SI effects of single-dose ketamine in different formulations/routes of administration by pooling results from randomized controlled trials… read more here.
Keywords: acute; intranasal esketamine; analysis; ketamine ... See more keywords
Comparative Effectiveness of Intravenous Ketamine and Intranasal Esketamine in Real-World Setting Among Patients with Treatment Refractory Depression
Sign Up to like & getrecommendations! Published in 2022 at "CNS Spectrums"
DOI: 10.1017/s1092852922000293
Abstract: Abstract Background Ketamine, an N-methyl-d-aspartate receptor antagonist, has been “repurposed” as a rapid-acting antidepressant for treatment-resistant depression (TRD). The s-enantiomer of ketamine, “esketamine,” was FDA approved for TRD and depressive symptoms in adults with major… read more here.
Keywords: ketamine esketamine; ketamine; remission; intranasal esketamine ... See more keywords
The efficacy and safety of adjunctive intranasal esketamine treatment in major depressive disorder: a systematic review and meta-analysis
Sign Up to like & getrecommendations! Published in 2022 at "Expert Opinion on Drug Safety"
DOI: 10.1080/14740338.2022.2058488
Abstract: ABSTRACT Introduction Intranasal (IN) esketamine represents an innovative treatment for individuals with treatment resistant depression and depression with suicidal ideation and behavior. Herein, we synthesize extant long-term studies (≥ 4 weeks) regarding this treatment. Research… read more here.
Keywords: treatment; intranasal esketamine; esketamine; meta analysis ... See more keywords
Intranasal esketamine for depression: Not so special K
Sign Up to like & getrecommendations! Published in 2022 at "Australasian Psychiatry"
DOI: 10.1177/10398562221093870
Abstract: Background Intranasal esketamine has been recently approved for the treatment of resistant depression. It is the only form of ketamine approved. The formulation costs around $600 per dose while plain injected ketamine, on which most… read more here.
Keywords: depression special; intranasal esketamine; esketamine; esketamine depression ... See more keywords